Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benadryl for infants

This article was originally published in The Tan Sheet

Executive Summary

Only one in 22 infants who were given Pfizer's Benadryl (diphenhydramine) to aid with sleep saw an improvement in their condition compared to three of 22 infants taking placebo, a study in the July Archives of Pediatrics & Adolescene Medicine finds. Dan Merenstein, MD, Johns Hopkins University, et al., conducted a double-blind, randomized, controlled clinical trial of the 44 children, ages 6 months to 15 months. Placebo or diphenhydramine was given to the babies 30 minutes before anticipated bed time. Parents reported on the number of night awakenings requiring parental assistance during a week of drug treatment and 2-4 weeks after its discontinuation. Secondary outcomes included parental overall happiness with sleep and improved sleep latency. The data safety monitoring board voted unanimously to stop the trial because of lack of effectiveness of diphenhydramine over placebo...

You may also be interested in...



Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel